Literature DB >> 1995741

Yersinia enterocolitica O:3: an emerging cause of pediatric gastroenteritis in the United States. The Yersinia enterocolitica Collaborative Study Group.

L A Lee1, J Taylor, G P Carter, B Quinn, J J Farmer, R V Tauxe.   

Abstract

After an outbreak of Yersinia enterocolitica infections among black children in Atlanta, a seven-hospital study was conducted to determine the importance of this pathogen in other communities with large black populations. Of 4841 stool specimens from patients with gastroenteritis examined between November 1989 and January 1990, Y. enterocolitica, Shigella, Campylobacter, and Salmonella were identified in 38, 49, 60, and 98 specimens, respectively; 34 (92%) of 37 Y. enterocolitica isolates were serotype O:3. Of the 38 patients with yersiniosis, 37 (97%) were children. Illnesses were clustered around the holidays, and 20 (62%) of 32 patients had been exposed to raw pork intestines in the 2 weeks before onset. Exposure was significantly associated with illness in a case-control study of eight patients identified at one hospital (P = .004). Infants less than or equal to 6 months old with yersiniosis were more likely to have immature-to-total neutrophil ratios greater than 0.50 than were infants of comparable age with salmonellosis (P = .02). Infrequently isolated in the past, Y. enterocolitica O:3 is emerging as an important enteric pathogen in this country, particularly among black children.

Entities:  

Mesh:

Year:  1991        PMID: 1995741     DOI: 10.1093/infdis/163.3.660

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  A dramatic increase of Yersinia enterocolitica serogroup O:8 infections in Poland.

Authors:  W Rastawicki; J Szych; R Gierczyński; N Rokosz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-10-24       Impact factor: 3.267

2.  A descriptive review of selected nonviral enteric illnesses reported in children in Quebec between 1999 and 2006.

Authors:  Henri Kaboré; Pascal Michel; Patrick Levallois; Pierre Déry; Pierre Payment; Germain Lebel
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

Review 3.  Salmonella, Shigella, and yersinia.

Authors:  John P Dekker; Karen M Frank
Journal:  Clin Lab Med       Date:  2015-04-02       Impact factor: 1.935

4.  Use of a single procedure for selective enrichment, isolation, and identification of plasmid-bearing virulent Yersinia enterocolitica of various serotypes from pork samples.

Authors:  S Bhaduri; B Cottrell; A R Pickard
Journal:  Appl Environ Microbiol       Date:  1997-05       Impact factor: 4.792

5.  Yersinia enterocolitica sepsis in a 3-week-old child.

Authors:  E C Thompson
Journal:  J Natl Med Assoc       Date:  1994-10       Impact factor: 1.798

6.  Murine neonates are highly resistant to Yersinia enterocolitica following orogastric exposure.

Authors:  Andrea Echeverry; Kurt Schesser; Becky Adkins
Journal:  Infect Immun       Date:  2007-02-26       Impact factor: 3.441

Review 7.  The virulence plasmid of Yersinia, an antihost genome.

Authors:  G R Cornelis; A Boland; A P Boyd; C Geuijen; M Iriarte; C Neyt; M P Sory; I Stainier
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

8.  Duration of carriage and transmission of Yersinia enterocolitica biotype 4, serotype 0:3 in dogs.

Authors:  S G Fenwick; P Madie; C R Wilks
Journal:  Epidemiol Infect       Date:  1994-12       Impact factor: 2.451

9.  Yersinia enterocolitica: a frequent seasonal stool isolate from children at an urban hospital in the southeast United States.

Authors:  B Metchock; D R Lonsway; G P Carter; L A Lee; J E McGowan
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

10.  Potential sources of sporadic human infection with Yersinia enterocolitica serovar O:8 in Aomori Prefecture, Japan.

Authors:  H Hayashidani; Y Ohtomo; Y Toyokawa; M Saito; K Kaneko; J Kosuge; M Kato; M Ogawa; G Kapperud
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.